daunorubicin has been researched along with luteolin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cahlikova, L; Chlebek, J; Havrankova, J; Hofman, J; Hostalkova, A; Lundova, T; Musilek, K; Novotna, E; Wsol, V; Zemanova, L | 1 |
| Chen, J; Zhang, W; Zhu, Y | 1 |
2 other study(ies) available for daunorubicin and luteolin
| Article | Year |
|---|---|
Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment.
Topics: Aldehyde Reductase; Aldo-Keto Reductases; Apigenin; Daunorubicin; Enzyme Inhibitors; Flavones; Flavonoids; HCT116 Cells; Humans; Luteolin; Molecular Conformation; Molecular Structure; Neoplasms | 2015 |
Binary Nanodrug-Delivery System Designed for Leukemia Therapy: Aptamer- and Transferrin-Codecorated Daunorubicin- and Luteolin-Coloaded Nanoparticles.
Topics: Animals; Cell Line, Tumor; Daunorubicin; Drug Delivery Systems; Leukemia; Ligands; Luteolin; Mice; Nanoparticles; Oligonucleotides; Transferrin | 2023 |